Emphysematous Cystitis in a Patient Receiving Cyclophosphamide

Emphysematous cystitis (EC) is a form of complicated urinary tract infection (UTI) well described in patients with diabetes. Other known risk factors include urinary tract obstruction, older age, and female gender. This case describes a patient who developed emphysematous cystitis while receiving in...

Descripción completa

Detalles Bibliográficos
Autor principal: Al Zein, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583972/
https://www.ncbi.nlm.nih.gov/pubmed/34790477
http://dx.doi.org/10.7759/cureus.18722
_version_ 1784597333029158912
author Al Zein, Said
author_facet Al Zein, Said
author_sort Al Zein, Said
collection PubMed
description Emphysematous cystitis (EC) is a form of complicated urinary tract infection (UTI) well described in patients with diabetes. Other known risk factors include urinary tract obstruction, older age, and female gender. This case describes a patient who developed emphysematous cystitis while receiving induction therapy with intravenous cyclophosphamide to treat antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that presented with rapidly progressive glomerulonephritis (RPGN). The association between cyclophosphamide therapy and emphysematous cystitis has only been reported twice in literature.
format Online
Article
Text
id pubmed-8583972
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85839722021-11-16 Emphysematous Cystitis in a Patient Receiving Cyclophosphamide Al Zein, Said Cureus Internal Medicine Emphysematous cystitis (EC) is a form of complicated urinary tract infection (UTI) well described in patients with diabetes. Other known risk factors include urinary tract obstruction, older age, and female gender. This case describes a patient who developed emphysematous cystitis while receiving induction therapy with intravenous cyclophosphamide to treat antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that presented with rapidly progressive glomerulonephritis (RPGN). The association between cyclophosphamide therapy and emphysematous cystitis has only been reported twice in literature. Cureus 2021-10-12 /pmc/articles/PMC8583972/ /pubmed/34790477 http://dx.doi.org/10.7759/cureus.18722 Text en Copyright © 2021, Al Zein et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Al Zein, Said
Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title_full Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title_fullStr Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title_full_unstemmed Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title_short Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
title_sort emphysematous cystitis in a patient receiving cyclophosphamide
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583972/
https://www.ncbi.nlm.nih.gov/pubmed/34790477
http://dx.doi.org/10.7759/cureus.18722
work_keys_str_mv AT alzeinsaid emphysematouscystitisinapatientreceivingcyclophosphamide

Ejemplares similares